...Drugs (LPAD). The aminoglycoside antibiotic came to Insmed via the company’s $84 million acquisition of Transave Inc....
...rinfibate and stopped selling the IGF-1 receptor agonist to new patients (see “Insmed combines with Transave”...

...the EU to treat NTM lung infection. Insmed gained Arikayce through its 2010 acquisition of Transave Inc....

...the EU to treat NTM lung infection. Insmed gained Arikayce through its 2010 acquisition of Transave Inc....

...the EU to treat NTM lung infection. Insmed gained Arikayce through its 2010 acquisition of Transave Inc....

...cystic fibrosis (CF) patients. Insmed gained the inhaled liposomal amikacin through its 2010 acquisition of Transave Inc....

...the U.S. to treat NTM lung infection. Insmed gained Arikace through its 2010 acquisition of Transave Inc....

...the U.S. to treat NTM lung infection. Insmed gained Arikace through its 2010 acquisition of Transave Inc....

...of the inhaled liposomal amikacin last month. Insmed gained Arikace through its 2010 acquisition of Transave Inc....

...the U.S. to treat NTM lung infection. Insmed gained Arikace through its 2010 acquisition of Transave Inc....

...NTM) lung infection. Insmed gained Arikace, an inhaled liposomal amikacin, through its 2010 acquisition of Transave Inc. BC...